UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER

Recommendations

Info

Presentations T cell repertoire diversification is associated with immune related toxicities following immune checkpoint inhibition in metastatic cancer patients Authors*: David Y. Oh, Jason Cham, Li Zhang, Grant Fong, Mark Klinger, Malek Faham, Lawrence Fong Pres #: 4362 Section: Presentation Date/Time: Tuesday, April 19: 3:50-4:05PM Location: New Orleans Theater C Presentation Type: Minisymposium Fong Lab Expertise: My lab focuses on how the immune system interacts with cancer as well as exploring tumor immunotherapies in mouse models and in patients. Our primary focus is in immunotherapy of GI and GU malignancies. We investigate how immunotherapies such as immune checkpoint inhibitors and cancer vaccines can enhance anti-tumor immunity both systemically and in the tumor microenvironment. Performing neoadjuvant immunotherapy trials, we determine how specific therapies can recruit immune effectors in cancer patients. Moreover, we have studied how clinical responders may differ from clinical non-responders. We are applying unbiased approaches to studying antigen-specific responses that are modulated in these patients and are currently developing biomarkers that may be predictive of clinical efficacy. http://hemonc.ucsf.edu/fonglab/ __________________________________________________________________________ Mechanism of PI3K activation by the HER3/ErbB3 receptor Authors*: Nicole Michael, Michael Hopkins, Natalia Jura Pres #: 4590 Section: 8 Presentation Date/Time: Wednesday, April 20: 8:00AM-12:00PM Location: Presentation Type: Poster Session Jura Lab Expertise: The main interest of our laboratory is to understand molecular principles of signal transduction events. We investigate them at the level of enzymatic function and molecular structure of signaling proteins. Our current focus is on understanding how membrane-associated kinases, such as receptor tyrosine kinases, assemble into functional complexes and interface with the plasma membrane. We also investigate alternative non-catalytic roles of kinase scaffolds and seek to identify small molecule inhibitors that target these poorly understood kinase functions in human diseases. http://www.cvri.ucsf.edu/~jura/lab/Jura_Lab_Home.html *UCSF authors in bold 34
Presentations Direct analysis of tumor immune infiltrates for “Exhausted” CD8+ T-Cells and BDCA3+ predicts responses in melanoma Authors*: Kimberly Loo, Katy K. Tsai, Adi Nosrati, Mariela Pauli, Robert Sanchez, Miranda Broz, Lorenzo Nardo, Miguel Pampaloni, Michael Alvarado, Paul Tumeh, Alain Algazi, Michael Rosenblum, Matthew Krummel, Adil Daud Pres #: 4883 Section: 22 Presentation Date/Time: Wednesday, April 20: 8:00AM-12:00PM Location: Presentation Type: Poster Session Daud Lab Expertise: Our group at UCSF is focused on developing new immunotherapy agents and specifically understanding the biology of the immune response to PD-1 in melanoma. We developed IL-12 gene therapy in melanoma and carried out the first in human clinical trial in 2005-2007. Based on this work, IL-12 electroporation is being explored in many cancers as an immune agent and as a combination treatment with PD-1 and other checkpoint inhibitors in melanoma. I have been involved in the development of anti- PD-1 antibodies for melanoma. With my colleagues Michael Rosenblum and Max Krummel at UCSF, we have developed a novel assay that profiles the intra-tumoral microenvironment in depth and can predict nonresponse to PD-1. We are currently exploring novel strategies for PD-1 non-responsive subsets of melanoma (and potentially other cancers). http://cancer.ucsf.edu/people/profiles/daud_adil.3622 __________________________________________________________________________ Interplay between ECM stiffness, miR-203 and mammographic density Authors*: Ivory Dean, Irene Acerbi, Alfred Au, Yunn-Yi Chen, Shelley Hwang, Valerie Weaver Pres #: 5100 Section: 30 Presentation Date/Time: Wednesday, April 20: 8:00AM-12:00PM Location: Presentation Type: Poster Session Weaver Lab Expertise: The extracellular matrix (ECM), the noncellular component of the microenvironment, influences cell growth, survival, migration and tissue-specific differentiation through a repertoire of cellular receptors including integrins, syndecans and discoidin receptors. We are exploring the molecular mechanisms whereby these ECM receptors modulate cell fate: specifically, how mechanical and topological properties of the matrix, which are related to its composition and organization, regulate the function of matrix receptors to alter cell behavior. Our research program is broadly divided into two fields of inquiry: (1) how matrix composition and organization influences mammary tissue development and tumor progression and (2) to clarify the role of matrix force on embryonic and adult stem cell fate. http://weaverlab.ucsf.edu *UCSF authors in bold 35
Page 1 and 2: UCSF HELEN DILLER FAMILY COMPREHENS
Page 3 and 4: HDFCCC Overview A Designated NCI Co
Page 5 and 6: HDFCCC Overview Core Capabilities S
Page 7 and 8: Presentations Presentations View fu
Page 9 and 10: Presentations Whole exome and targe
Page 11 and 12: Presentations SRC mediates intrinsi
Page 13 and 14: Presentations Deregulated Myc is an
Page 15 and 16: Presentations BRM loss promotes tum
Page 17 and 18: Presentations HER3 is a functional
Page 19 and 20: Presentations MicroRNA-466 regulate
Page 21 and 22: Presentations Systematic search for
Page 23 and 24: Presentations Toxicity, bioavailabi
Page 25 and 26: Presentations The genetic evolution
Page 27 and 28: Presentations A stem cell program i
Page 29 and 30: Presentations Inhibition of fatty-a
Page 31 and 32: Presentations Genetic prediction of
Page 33: Presentations Overcoming resistance
Page 37: Presentations Caffeic acid phenethy

UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER

Create successful ePaper yourself

Delete template?

Save as template?